Subchondral Sclerosis: Imaging, Pathophysiology & Link to Osteoarthritis

Subchondral sclerosis is a radiographic and histologic finding of increased bone density and thickening in the subchondral plate—the layer of bone directly beneath the articular cartilage. It is a hallmark of osteoarthritis (OA) and reflects the bone's response to altered joint biomechanics.

Pathophysiology

1. Cartilage degeneration (fibrillation, loss of proteoglycans, collagen disruption) → loss of shock absorption.
2. Abnormal load transmission → increased stress on subchondral bone.
3. Bone remodeling response: Osteoblast activation → increased bone formation, trabecular thickening, reduced marrow space.
4. Microdamage accumulation: Stiffened subchondral bone fails to dissipate energy → further cartilage damage (vicious cycle).
5. Vascular invasion & nerve ingrowth into calcified cartilage → pain generation (subchondral bone is innervated; cartilage is not).

Imaging Findings

Modality	Appearance
Radiograph (X-ray)	Increased radiopacity (whiteness) of subchondral bone; "eburnation" (polished ivory-like) in advanced cases; joint space narrowing, osteophytes, cysts often coexist.
MRI	Low signal on all sequences (dense bone); associated bone marrow lesions (BMLs) = high T2/STIR signal (edema, fibrosis, microfractures) — strongly correlate with pain.
CT	Excellent cortical/trabecular detail; quantifies sclerosis volume.
DEXA/QCT	Localized high BMD; distinct from systemic osteoporosis.

Clinical Significance

• Diagnostic criterion for OA (Kellgren-Lawrence grade ≥2 includes sclerosis).
• Pain generator: BMLs + sclerosis + synovitis = primary pain sources in OA (cartilage is aneural).
• Progression marker: Worsening sclerosis/BMLs predict faster joint space loss & joint replacement.
• Differential: Osteosclerosis (systemic), osteoblastic metastases, Paget's, osteoid osteoma, stress fracture, osteomyelitis.

Management Implications

• Symptomatic OA: Weight loss, exercise (quad strengthening), NSAIDs, IA corticosteroids, IA hyaluronic acid, duloxetine.
• Targeting subchondral bone: Bisphosphonates (zoledronic acid – modest pain/structure benefit in trials), Strontium ranelate (withdrawn in many regions), Anti-NGF antibodies (investigational).
• Surgical: High tibial osteotomy (realign load), Unicompartmental/Total knee arthroplasty (definitive).
• Emerging: Subchondroplasty (calcium phosphate injection into BMLs) – short-term pain relief in select patients.

Key Distinction

Subchondral sclerosis ≠ Osteosclerosis (systemic). It is a localized, reactive adaptation to joint-level mechanical and inflammatory stressors. Its presence confirms structural OA progression and guides prognosis/treatment.